Research graph
References from Six Degrees of Separation: The Oxygen Effect in the Development of Radiosensitizers. Local targets link to admitted publications; unresolved targets remain external evidence.
The role of hypoxia inducible factor-1 in cell metabolism—a possible target in cancer therapy
10.1517/14728222.10.4.583 · 2006 · External reference
Hypoxia: targeting the tumour
10.2174/187152006777698169 · 2006 · External reference
The HIF pathway in cancer
10.1016/j.semcdb.2005.03.001 · 2005 · External reference
Hypoxia and oxidative stress
2001 · External reference
Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements
1991 · External reference
New insights into factors influencing the clinically relevant oxygen enhancement ratio
10.1016/s0167-8140(97)00185-0 · 1998 · External reference
The histological structure of some human lung cancers and the possible implications for radiotherapy
10.1038/bjc.1955.55 · 1955 · External reference
Hyperbaric oxygen and radiotherapy
10.1007/s00066-005-1277-y · 2005 · External reference
Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a phase II nonrandomized study
10.1016/j.ijrobp.2008.06.1950 · 2009 · External reference
a novel biologybased approach in radiotherapy
10.1016/s1470-2045(02)00929-4 · 2002 · External reference
Anemia, tumor hypoxemia, and the cancer patient
10.1016/j.ijrobp.2005.04.049 · 2005 · External reference
Erythropoietin in cancer patients: pros and cons
10.1097/cco.0b013e32833aa9de · 2010 · External reference
Results of the phase III ENRICH (RT-016) study of efaproxiral administered concurrent with Whole Brain Radiation Therapy (WBRT) in women with brain metastases from breast cancer
10.1016/j.ijrobp.2008.06.880 · 2008 · External reference
Anti-angiogenic properties of myo-inositol trispyrophosphate in ovo and growth reduction of implanted glioma
10.1016/j.febslet.2007.01.079 · 2007 · External reference
Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes
10.1073/pnas.0607109103 · 2006 · External reference
New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms
2008 · External reference
10.3892/or_00000968
10.3892/or_00000968 · 2010 · External reference
Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II)
10.3892/ijo_00000186 · 2009 · External reference
Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro 7-0582
10.2307/3574253 · 1975 · External reference
Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses
10.1038/bjc.1977.90 · 1977 · External reference
Clinical trials of radiosensitizers: what should we expect?
10.1016/0360-3016(84)90063-4 · 1984 · External reference
Radiation sensitization with redox modulators: a promising approach
10.1016/j.ijrobp.2005.10.013 · 2006 · External reference
Generation of nitro radical anions of some 5-nitrofurans, 2- and 5-nitroimidazoles by norepinephrine, dopamine, and serotonin
1987 · External reference
Reversible metronidazole-induced encephalopathy
10.1016/j.neurad.2007.01.127 · 2007 · External reference
Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy
10.1212/wnl.45.3.588 · 1995 · External reference
AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial
10.1016/j.radonc.2006.11.007 · 2007 · External reference
Exploiting tumour hypoxia in cancer treatment
10.1038/nrc1367 · 2004 · External reference
Palladium or platinum exacerbates hydroxyl radical mediated DNA damage
10.1016/s0891-5849(96)00553-9 · 1997 · External reference
Proteomic analysis of lanthanum citrate-induced apoptosis in human cervical carcinoma SiHa cells
10.1007/s10534-010-9368-3 · 2010 · External reference
Lanthanides as anticancer agents
10.2174/156801105774574694 · 2005 · External reference
Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species
10.1016/s0360-3016(01)01810-7 · 2001 · External reference
Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy
10.1016/s0006-2952(99)00314-7 · 2000 · External reference
Motexafin gadolinium: gadolinium(III) texaphyrin, gadolinium texaphyrin
10.2165/00126839-200405010-00012 · 2004 · External reference
A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging
1999 · External reference
Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity
10.1016/s0360-3016(00)01566-2 · 2001 · External reference
Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent
2000 · External reference
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases
10.1200/jco.2003.12.122 · 2003 · External reference
Potential bioreductive alkylating agents
1972 · External reference
Mitomycin antibiotic reductive potential and related pharmacological activities
10.1016/s0026-895x(25)11035-3 · 1990 · External reference
Differential enzymatic reductions governing the differential hypoxia-selective cytotoxicities of phenazine 5,10-dioxides
10.1021/tx800199v · 2008 · External reference
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9
10.1093/jnci/88.5.259 · 1996 · External reference
Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures
10.1021/jm049549p · 2005 · External reference
Hypoxia-selective antitumor agents
1997 · External reference
Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway
2008 · External reference
Bioactivation as a model for drug design bioreductive alkylation
10.1126/science.877572 · 1977 · External reference
Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of dna
10.1126/science.145.3627.55 · 1964 · External reference
Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro
1985 · External reference
Porfiromycin as an adjunct to radiotherapy in young and old mice
10.1016/0531-5565(93)90035-c · 1993 · External reference
Preclinical studies of porfiromycin as an adjunct to radiotherapy
10.2307/3577481 · 1988 · External reference
Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial
10.1016/j.ijrobp.2004.07.730 · 2005 · External reference
Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck
10.1002/(sici)1520-6823(1997)5:5<235::aid-roi4>3.0.co;2-z · 1997 · External reference
Apaziquone for non-muscle invasive bladder cancer: a critical review
10.1517/13543784.17.7.1085 · 2008 · External reference
Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase
1994 · External reference
The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins
10.1016/0360-3016(92)90495-4 · 1992 · External reference
DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas
10.1016/0959-8049(92)90049-8 · 1992 · External reference
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09
10.1093/jnci/86.12.906 · 1994 · External reference
Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates
10.1016/j.urology.2007.12.062 · 2009 · External reference
Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer
10.1007/s00345-009-0382-4 · 2009 · External reference
Unresolved reference
External reference
SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells
10.1016/0360-3016(86)90267-1 · 1986 · External reference
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
10.1038/bjc.1993.220 · 1993 · External reference
Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation
10.1016/0360-3016(91)90057-b · 1991 · External reference
Tirapazamine: a novel agent targeting hypoxic tumor cells
10.1517/13543780802567250 · 2009 · External reference
Exploring vascular dysfunction caused by tirapazamine
10.1016/j.mvr.2007.09.006 · 2008 · External reference
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins
10.1021/jm800967h · 2008 · External reference
Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors
10.1158/1078-0432.ccr-10-1439 · 2010 · External reference
Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxiatargeted anticancer drugs
10.1093/jnci/djj306 · 2006 · External reference
Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase
10.1021/jm800496s · 2008 · External reference
AQ4N: a new approach to hypoxiaactivated cancer chemotherapy
10.1054/bjoc.2000.1564 · 2000 · External reference
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
2000 · External reference
DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells
10.1038/bjc.1996.87 · 1996 · External reference
Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation
1996 · External reference
AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo
10.1038/bjc.1995.280 · 1995 · External reference
A phase 1 open-label, accelerated doseescalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies
10.1158/1078-0432.ccr-08-0483 · 2008 · External reference
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study
10.1158/1078-0432.ccr-07-4020 · 2008 · External reference
Banoxantrone (AQ4N), tissue CYP 450 targeted prodrug: the results of a phase I study using an accelerated dose escalation
10.1200/jco.2006.24.18_suppl.2011 · 2006 · External reference
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia
10.1073/pnas.90.9.4304 · 1993 · External reference
Development of novel therapeutic strategies that target HIF-1
10.1517/14728222.10.2.267 · 2006 · External reference
Inhibiting the hypoxia response for cancer therapy: the new kid on the block
10.1158/1078-0432.ccr-09-1650 · 2009 · External reference
Development of HIF-1 inhibitors for cancer therapy
10.1111/j.1582-4934.2009.00876.x · 2009 · External reference
PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells
10.1002/ijc.23807 · 2008 · External reference
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice
10.1097/jto.0b013e3181dc211f · 2010 · External reference
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha
10.1158/1535-7163.mct-07-0463 · 2008 · External reference
Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1a
10.1200/jco.2010.28.15_suppl.3076 · 2010 · External reference
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer
10.1158/1535-7163.mct-09-0768 · 2010 · External reference
The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects
10.1158/1535-7163.mct-08-0981 · 2009 · External reference
IAP proteins: blocking the road to death's door
10.1038/nrm830 · 2002 · External reference
Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1alpha
10.1097/01.mpa.0000202961.71600.9b · 2006 · External reference
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
1998 · External reference
XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer
10.1038/sj.onc.1207929 · 2004 · External reference
Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo
2003 · External reference
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
2000 · External reference
Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer
10.1111/j.1349-7006.2010.01789.x · 2011 · External reference
Unresolved reference
External reference
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs
10.1021/jm701028q · 2008 · External reference
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
10.1182/blood-2010-02-269126 · 2010 · External reference
Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302
10.1007/s12011-009-8544-1 · 2010 · External reference
Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers
10.1517/13543770902824172 · 2009 · External reference
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3
10.1158/0008-5472.can-09-3237 · 2010 · External reference
Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine
10.1016/j.ijrobp.2007.05.049 · 2007 · External reference
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
10.1007/s00280-009-1188-1 · 2010 · External reference
Unresolved reference
External reference
Solution structure of a nitrous acid induced DNA interstrand cross-link
10.1093/nar/gkh606 · 2004 · External reference
Therapeutic potential of nitric oxide in cancer
10.1016/j.drup.2006.05.003 · 2006 · External reference
Nitric oxide and S-nitrosylation: excitotoxic and cell signaling mechanism
10.1016/s0248-4900(03)00004-2 · 2003 · External reference
Nitric oxide stimulates Ca(2+)-independent synaptic vesicle release
10.1016/0896-6273(94)90440-5 · 1994 · External reference
Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate
1989 · External reference
Nitric oxide: NO apoptosis or turning it ON?
10.1038/sj.cdd.4401261 · 2003 · External reference
Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-κB/Snail/YY1/RKIP circuitry
10.1016/j.niox.2010.10.001 · 2011 · External reference
Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma
10.1038/bjc.1997.406 · 1997 · External reference
Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling
10.1158/1078-0432.ccr-06-1807 · 2007 · External reference
Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases
10.1016/j.niox.2008.04.018 · 2008 · External reference
Radiosensitization of HT-29 cells and xenografts by the nitric oxide donor DETANONOate
10.1002/jso.21318 · 2009 · External reference
Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI
10.1016/s0360-3016(00)00694-5 · 2000 · External reference
5-Nitroimidazoles. II: Unexpected reactivity of ronidazole and dimetridazole with thiols
10.1139/v93-174 · 1993 · External reference
Production of nitric oxide by hypoxic radiosensitizer sanazole
2004 · External reference
Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study
10.1016/s1470-2045(07)70001-3 · 2007 · External reference
Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer
10.1016/j.urology.2009.03.004 · 2009 · External reference
Regulation of nitric oxide signalling by thrombospondin 1: implications for antiangiogenic therapies
10.1038/nrc2561 · 2009 · External reference
Increasing survival of ischemic tissue by targeting CD47
10.1161/01.res.0000259579.35787.4e · 2007 · External reference
Inhibitors of angiogenesis: new hopes for oncologists, new challenges for anesthesiologists
10.1097/aln.0b013e3181ed098d · 2010 · External reference
Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury
10.2353/ajpath.2008.080237 · 2008 · External reference
In vivo radiation protection by nitric oxide modulation
1994 · External reference
Unresolved reference
2011 · External reference
Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling
10.1126/scitranslmed.3000139 · 2009 · External reference
Hypoxic radiosensitization: adored and ignored
10.1200/jco.2007.12.7878 · 2007 · External reference
